Cargando…

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis

Introduction: Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is a class of hypoglycemic medications. Semaglutide once-weekly (QW) and liraglutide once-daily (OD) significantly improved glycemic control compared to placebo. To date, no long-term phase III trials directly comparing semaglutide an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsugair, Hassan A., Alshugair, Ibrahim F., Alharbi, Turki J., Bin Rsheed, Abdulaziz M., Tourkmani, Ayla M., Al-Madani, Wedad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466858/ https://www.ncbi.nlm.nih.gov/pubmed/34574899 http://dx.doi.org/10.3390/healthcare9091125

Ejemplares similares

Prevalence of retinopathy and associated risk factors among high- and low-risk patients with type 2 diabetes mellitus: An observational study
por: Alghamdi, Salem A., et al.
Publicado: (2021)

Utilizing diabetes registry for exploring sociodemographic and clinical characteristics of type II diabetic patients in Saudi Arabia
por: Tourkmani, Ayla M., et al.
Publicado: (2021)

Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia
por: Albarkah, Yasser A., et al.
Publicado: (2019)

Sociodemographic and clinical predictors of refractory type 2 diabetes patients: Findings from a case-control study
por: Alharbi, Turki J., et al.
Publicado: (2021)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia
por: Faleh AlMutairi, Manal, et al.
Publicado: (2021)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome
por: Bin rsheed, Abdulaziz, et al.
Publicado: (2017)

Impact of an integrated care program on glycemic control and cardiovascular risk factors in patients with type 2 diabetes in Saudi Arabia: an interventional parallel-group controlled study
por: Tourkmani, Ayla M., et al.
Publicado: (2018)

The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus
por: Alharbi, Turki J., et al.
Publicado: (2018)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center
por: AlOlaiwi, Lina A., et al.
Publicado: (2018)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Prevalence of COVID-19 Infection among Patients with Diabetes and Their Vaccination Coverage Status in Saudi Arabia: A Cross-Sectional Analysis from a Hospital-Based Diabetes Registry
por: Tourkmani, Ayla M., et al.
Publicado: (2022)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Awareness of basic life support and cardiopulmonary resuscitation among female secondary school students in government schools in Riyadh city, KSA
por: Al Harbi, Nouf, et al.
Publicado: (2018)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

IDF21-0295 Cost-effectiveness of telemedicine care for uncontrolled type 2 diabetes mellitus patients during the COVID-19 pandemic
por: Almutairi, M., et al.
Publicado: (2022)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Determinants of family medicine physicians’ knowledge and application of asthma management guidelines at primary healthcare centers in Riyadh, Saudi Arabia
por: Alrabiah, Abdulaziz M., et al.
Publicado: (2018)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Cornejo-Estrada, Alejandra, et al.
Publicado: (2023)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
por: Evans, Marc, et al.
Publicado: (2023)

Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Barboza, Joshuan J., et al.
Publicado: (2022)

The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis
por: Kennedy, Cormac, et al.
Publicado: (2023)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery
por: Alsheikh, Khalid, et al.
Publicado: (2021)

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
por: Jensen, Anders Boisen, et al.
Publicado: (2023)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Potentially inappropriate medications prescribed for elderly patients through family physicians
por: Al Odhayani, Abdulaziz, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ikp4hjvm3adbaq9gad9f1flpgr